Cargando…

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study

BACKGROUND: Treatment options for patients suffering from progressive forms of multiple sclerosis (MS) remain inadequate. Mast cells actively participate in the pathogenesis of MS, in part because they release large amounts of various mediators that sustain the inflammatory network. Masitinib, a sel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vermersch, Patrick, Benrabah, Rabah, Schmidt, Nicolas, Zéphir, Hélène, Clavelou, Pierre, Vongsouthi, Cyrille, Dubreuil, Patrice, Moussy, Alain, Hermine, Olivier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3467179/ https://www.ncbi.nlm.nih.gov/pubmed/22691628 http://dx.doi.org/10.1186/1471-2377-12-36

Ejemplares similares

Neuroprotective effect of masitinib in rats with postischemic stroke
por: Kocic, Ivan, et al.
Publicado: (2014)

Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial
por: Vermersch, Patrick, et al.
Publicado: (2022)

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial
por: Piette, François, et al.
Publicado: (2011)

Long-term survival analysis of masitinib in amyotrophic lateral sclerosis
por: Mora, Jesus S., et al.
Publicado: (2021)

Depression in Patients with Mastocytosis: Prevalence, Features and Effects of Masitinib Therapy
por: Moura, Daniela Silva, et al.
Publicado: (2011)

Masitinib Combined with Standard Gemcitabine Chemotherapy: In Vitro and In Vivo Studies in Human Pancreatic Tumour Cell Lines and Ectopic Mouse Model
por: Humbert, Martine, et al.
Publicado: (2010)

Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
por: Dubois, Bruno, et al.
Publicado: (2023)

Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study
por: Tebib, Jacques, et al.
Publicado: (2009)

Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
por: Dubreuil, Patrice, et al.
Publicado: (2009)

Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
por: Dubois, Bruno, et al.
Publicado: (2023)

Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis
por: Trias, Emiliano, et al.
Publicado: (2016)

Efficacy and Safety of Masitinib in Corticosteroid-Dependent Severe Asthma: A Randomized Placebo-Controlled Trial
por: Davidescu, Lavinia, et al.
Publicado: (2022)

Decrease of cocaine, but not heroin, self-administration and relapse by the tyrosine kinase inhibitor masitinib in male Sprague Dawley rats
por: Belin-Rauscent, A., et al.
Publicado: (2018)

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer
por: Deplanque, G., et al.
Publicado: (2015)

Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis
por: Brochet, Bruno, et al.
Publicado: (2017)

More about masitinib
por: Walker, Ulrich A
Publicado: (2009)

Does Fatigue Complaint Reflect Memory Impairment in Multiple Sclerosis?
por: Jougleux-Vie, Caroline, et al.
Publicado: (2014)

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial
por: Adenis, A., et al.
Publicado: (2014)

Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive Phenotype
por: Brochet, Bruno, et al.
Publicado: (2022)

Interaction of Masitinib with Organic Cation Transporters
por: Harrach, Saliha, et al.
Publicado: (2022)

Masitinib Inhibits Hepatitis A Virus Replication
por: Sasaki-Tanaka, Reina, et al.
Publicado: (2023)

MasitinibL shows promise as a drug-like analog of masitinib that elicits comparable SARS-Cov-2 3CLpro inhibition with low kinase preference
por: Durojaye, Olanrewaju Ayodeji, et al.
Publicado: (2023)

Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
por: Clavelou, Pierre, et al.
Publicado: (2023)

Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro
por: Milovancev, Milan, et al.
Publicado: (2016)

Disability progression in multiple sclerosis patients using early first‐line treatments
por: Lefort, Mathilde, et al.
Publicado: (2022)

Five-year outcome in the copaxone observatory: a nationwide cohort of patients with multiple sclerosis starting treatment with glatiramer acetate in France
por: Lebrun-Frenay, Christine, et al.
Publicado: (2019)

ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?
por: Petrov, Dmitry, et al.
Publicado: (2017)

Development of Masitinib Derivatives with Enhanced M(pro) Ligand Efficiency and Reduced Cytotoxicity
por: Menendez, Cintia A., et al.
Publicado: (2023)

Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis
por: Januel, Edouard, et al.
Publicado: (2023)

Lumbar punctures: use and diagnostic efficiency in emergency medical departments
por: Majed, Bilal, et al.
Publicado: (2009)

Extensive myelitis associated with anti-NMDA receptor antibodies
por: Outteryck, Olivier, et al.
Publicado: (2013)

Medical approach to the treatment of feline injection site sarcoma with masitinib: a case report
por: Ledoux, Jean-Marie, et al.
Publicado: (2014)

Effects of Tyrosine Kinase Inhibitor-masitinib Mesylate on Canine Mammary Tumour Cell Lines
por: Ustun-Alkan, Fulya, et al.
Publicado: (2021)

Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2
por: Drayman, Nir, et al.
Publicado: (2021)

Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance
por: KATHAWALA, RISHIL J., et al.
Publicado: (2014)

Proinflammatory B-cell profile in the early phases of MS predicts an active disease
por: Guerrier, Thomas, et al.
Publicado: (2017)

Comparison of Simoa(TM) and Ella(TM) to assess serum neurofilament‐light chain in multiple sclerosis
por: Gauthier, Audrey, et al.
Publicado: (2021)

Characterization of in vivo metabolites in rat urine following an oral dose of masitinib by liquid chromatography tandem mass spectrometry
por: Kadi, Adnan A., et al.
Publicado: (2018)

Masitinib analogues with the N-methylpiperazine group replaced – A new hope for the development of anti-COVID-19 drugs
por: Gurung, Arun Bahadur, et al.
Publicado: (2023)

Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
por: Fissolo, Nicolás, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kk382n3s0t0pr11d79p9vm4sv5